Literature DB >> 19280084

Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model.

Bodo Cremers1, Melanie Biedermann, Dirk Mahnkopf, Michael Böhm, Bruno Scheller.   

Abstract

BACKGROUND: Drug-eluting balloon (DEB) catheters coated with paclitaxel in a water-soluble matrix have shown beneficial effects in the treatment and prevention of restenosis in the porcine coronary overstretch model and in clinical trials. Adherence of paclitaxel, same dose, on another recently introduced coated percutaneous coronary intervention (PCI) catheter (DIOR) is mediated by a roughened balloon surface. Only scarce experimental and clinical data has been published on the new coating method. The aim of the present study was to compare the safety and efficacy of the two coatings in the porcine model. METHODS AND
RESULTS: Twenty-eight stainless steel stents were implanted in the left anterior descending and circumflex coronary arteries of 14 domestic pigs using either matrix-coated (n = 8), roughened DEB (n = 9), or uncoated PCI catheters, which served as control (n = 11). After 28 days, quantitative angiography and histomorphometry of the stented arteries were performed. Matrix-coated DEB led to a highly significant (P < 0.01) reduction of all parameters indicating neointimal proliferation compared to both, uncoated control and the roughened DEB; late lumen loss in-segment was 0.4 +/- 0.2, 1.9 +/- 0.5, and 1.4 +/- 0.5 mm, respectively. In contrast, the roughened DEB failed to produce statistically significant effects on angiographic measures of stenosis or morphometric parameters such as maximal neointimal thickness and luminal area, except for neointimal area (5.7 +/- 1.5 mm(2) in the control group, 4.1 +/- 1.7 mm(2) roughened DEB, P < 0.05 vs. control, and 2.5 +/- 0.8 mm(2) matrix-coated DEB, P < 0.01 vs. control).
CONCLUSION: Inhibition of neointimal proliferation in the porcine coronary overstretch model by paclitaxel depends critically on the coating method.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19280084     DOI: 10.1007/s00392-009-0008-2

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  17 in total

1.  Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation.

Authors:  Bruno Scheller; Ulrich Speck; Alexander Schmitt; Michael Böhm; Georg Nickenig
Journal:  J Am Coll Cardiol       Date:  2003-10-15       Impact factor: 24.094

2.  Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter.

Authors:  Bruno Scheller; Christoph Hehrlein; Wolfgang Bocksch; Wolfgang Rutsch; Dariush Haghi; Ulrich Dietz; Michael Böhm; Ulrich Speck
Journal:  N Engl J Med       Date:  2006-11-13       Impact factor: 91.245

3.  Hotline update of clinical trials and registries presented at the ACC and SCAI-ACCi2 meeting 2008 in Chicago.

Authors:  Yvonne P Clever; Stephan Rosenkranz; Michael Böhm; Bruno Scheller
Journal:  Clin Res Cardiol       Date:  2008-05-15       Impact factor: 5.460

4.  Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis.

Authors:  A W Heldman; L Cheng; G M Jenkins; P F Heller; D W Kim; M Ware; C Nater; R H Hruban; B Rezai; B S Abella; K E Bunge; J L Kinsella; S J Sollott; E G Lakatta; J A Brinker; W L Hunter; J P Froehlich
Journal:  Circulation       Date:  2001-05-08       Impact factor: 29.690

5.  In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia.

Authors:  R Kornowski; M K Hong; F O Tio; O Bramwell; H Wu; M B Leon
Journal:  J Am Coll Cardiol       Date:  1998-01       Impact factor: 24.094

6.  Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries.

Authors:  Ulrich Speck; Bruno Scheller; Claudia Abramjuk; Christoph Breitwieser; Juergen Dobberstein; Michael Boehm; Bernd Hamm
Journal:  Radiology       Date:  2006-08       Impact factor: 11.105

7.  Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro.

Authors:  Taisuke Mori; Yoshiyuki Kinoshita; Ai Watanabe; Takeshi Yamaguchi; Kenichi Hosokawa; Hideo Honjo
Journal:  Cancer Chemother Pharmacol       Date:  2006-03-14       Impact factor: 3.333

8.  Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model.

Authors:  R S Schwartz; K C Huber; J G Murphy; W D Edwards; A R Camrud; R E Vlietstra; D R Holmes
Journal:  J Am Coll Cardiol       Date:  1992-02       Impact factor: 24.094

9.  Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis.

Authors:  Bruno Scheller; Ulrich Speck; Claudia Abramjuk; Ulrich Bernhardt; Michael Böhm; Georg Nickenig
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690

10.  Short- and long-term effects of a novel paclitaxel coated stent in the porcine coronary model.

Authors:  Bruno Scheller; Michael Kühler; Bodo Cremers; Dirk Mahnkopf; Michael Böhm; Michael Boxberger
Journal:  Clin Res Cardiol       Date:  2007-12-17       Impact factor: 5.460

View more
  19 in total

1.  Opportunities and limitations of drug-coated balloons in interventional therapies.

Authors:  B Scheller
Journal:  Herz       Date:  2011-05       Impact factor: 1.443

2.  Delivery of paclitaxel from cobalt-chromium alloy surfaces without polymeric carriers.

Authors:  Gopinath Mani; Celia E Macias; Marc D Feldman; Denes Marton; Sunho Oh; C Mauli Agrawal
Journal:  Biomaterials       Date:  2010-04-15       Impact factor: 12.479

Review 3.  Drug-coated balloons for coronary and peripheral interventional procedures.

Authors:  Jochen Wöhrle
Journal:  Curr Cardiol Rep       Date:  2012-10       Impact factor: 2.931

4.  Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter.

Authors:  Bodo Cremers; John L Toner; Lewis B Schwartz; Randolf von Oepen; Ulrich Speck; Nicola Kaufels; Yvonne P Clever; Dirk Mahnkopf; Michael Böhm; Bruno Scheller
Journal:  Clin Res Cardiol       Date:  2012-06       Impact factor: 5.460

5.  Drug eluting balloons for the treatment of coronary artery disease: What can we expect?

Authors:  Alexander Joost; Volkhard Kurowski; Peter W Radke
Journal:  World J Cardiol       Date:  2010-09-26

6.  Compassionate use of a paclitaxel coated balloon in patients with refractory recurrent coronary in-stent restenosis.

Authors:  Yvonne P Clever; Bodo Cremers; Wolfgang von Scheidt; Michael Böhm; Ulrich Speck; Bruno Scheller
Journal:  Clin Res Cardiol       Date:  2013-09-26       Impact factor: 5.460

7.  Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points.

Authors:  J M Siller-Matula; I Tentzeris; B Vogel; S Schacherl; R Jarai; A Geppert; G Unger; K Huber
Journal:  Clin Res Cardiol       Date:  2010-04-20       Impact factor: 5.460

8.  Coronary stenting with the sirolimus-eluting stent in patients with restenosis after intracoronary brachytherapy: results from the prospective multicentre German Cypher Stent Registry.

Authors:  Ralf Zahn; Christian W Hamm; Uwe Zeymer; Gert Richardt; Malte Kelm; Benny Levenson; Tassilo Bonzel; Ulrich Tebbe; Georg Sabin; Christoph A Nienaber; Thomas Pfannebecker; Jochen Senges
Journal:  Clin Res Cardiol       Date:  2009-10-31       Impact factor: 5.460

9.  Drug-coated Balloon-only Angioplasty for Native Coronary Disease Instead of Stents.

Authors:  Upul Wickramarachchi; Simon Eccleshall
Journal:  Interv Cardiol       Date:  2016-10

Review 10.  Drug-coated balloon therapy in coronary and peripheral artery disease.

Authors:  Robert A Byrne; Michael Joner; Fernando Alfonso; Adnan Kastrati
Journal:  Nat Rev Cardiol       Date:  2013-11-05       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.